Wecare Probiotics Testing Center Earns CNAS/ISO 17025 Accreditation, Reinforcing Commitment to Global Quality Standards

In a significant advancement for probiotic science and quality assurance, Wecare Probiotics proudly announces that Wecare Probiotics Testing Center has achieved the internationally recognized CNAS/ISO 17025 accreditation. This milestone certifies that the laboratory’s technical competence, quality management systems, and testing procedures meet rigorous global standards, further strengthening trust and reliability across the health and nutrition industry.

ISO 17025 is the leading global standard for testing and calibration laboratories, affirming that results are both scientifically valid and internationally accepted. Wecare Probiotics is a company built on the mission of “Quality Probiotics, Quality Life”—this accreditation shows our unwavering commitment to precision, transparency, and excellence in every stage of research, development, and production.

The Wecare Probiotics Testing Center operates within a 3,000+ square-meter independent facility, supported by a dedicated team of over 50 specialists in microbiology, analytical chemistry, and biotechnology. The center is equipped with state-of-the-art technologies, including:

• Three D-level cleanrooms and stability testing laboratories

• Advanced instrumentation such as whole genome sequencers, GC-MS, ICP-MS, FTIR, and flow cytometers

• Comprehensive testing services covering probiotic enumeration, strain identification, purity analysis, and physicochemical and microbiological evaluations

With this accreditation, the center now provides:

•  Authoritative technical support for industry-wide quality control

•  Internationally recognized and mutually accepted test data

•  Reliable, traceable, and transparent testing services for partners and clients

•  Enhanced product credibility and global market competitiveness

As one of the three core platforms within Wecare Probiotics, the Testing Center plays a vital role in ensuring that innovative probiotic formulations—such as the clinically studied Akkermansia muciniphila Akk11—are developed, validated, and delivered with scientific rigor and operational integrity.

This achievement not only elevates Wecare Probiotics' position in the global microbiome landscape but also reinforces our pledge to deliver safe, effective, and trusted probiotic solutions—backed by world-class science and an uncompromising dedication to quality.